Personalized Medicine - Opening Doors and Overcoming Challenges

Personalized Medicine - Opening Doors and Overcoming Challenges

Summary

Over the last 20 years personalized medicine has grown as tool in patient treatment. Personalized medicine uses a patient’s genetic information to help tailor treatment to avoid side effects, identify what treatments will and won’t work and establish a pre-disposition towards certain diseases.

Personalized medicine has been focused to a great degree in the oncology area, where on average an individual patient may find more than 70% of medicines ineffective for them. In the last few years this has begun to change as more personalized medicines have been developed outside of the oncology field. The spread of personalized medicine to other fields has increased the challenge of physician uptake, with many GPs not feeling comfortable ordering genetic tests.

Personalized medicine faces a number of road blocks, including the issues of physician uptake of diagnostics, challenges for clinical trials, public controversy and, most significantly, lack of reimbursement by payers.

CBR Pharma Insights’ report, “Personalized Medicine - Opening Doors and Overcoming Challenges” provides insights & analysis on this important issue and the strategies pharmaceutical companies can employ to support the future growth of their business.

Scope

- Overview and timeline of personalized medicine
- Issues and case studies related to personalized medicine
- Key topics covered include identification of adverse reactions, identification of pre-disposition towards diseases and treatment options that will and will not work
- Healthcare legislation related to personalized medicine
- Challenges and strategies to overcome
- Future outlook

Reasons to buy

- Gain access to a fully sourced, executive assessment of the “in’s and out’s” of personalized medicine
- Benefit from CBR’s evaluation of the key areas where personalized medicine is used through our case study analysis
- Identify opportunities where your company can strengthen its portfolio through the use of personalized medicine
- Understand the recent US legislature which will have the greatest impact on the growth of personalized medicine
- Identify the road blocks to the growth of personalized medicine and what can be done to overcome them

Executive Summary

Introduction
What is Personalized Medicine
Timeline of Personalized Medicine

The Spectrum of Personalized Medicine
Identifying Adverse Reactions
Controversy/Issues
Case Study: warfarin
Case Study: Ziagen

Identifying What Treatment will Work
Controversy/Issues
Case Study: Herceptin
Case Study: Erbitux

Identifying What Treatment won’t Work
Controversy/Issues
Case Study: Plavix
Case Study: beta interferon

Identifying Pre-disposition towards disease
Controversy/Issues
Case Study: Breast Cancer
Case Study: Alzheimer’s Disease

Health care Legislation and Personalized Medicine
Health Insurance Portability and Accountability Act 1996
Genetic Information Non-discrimination Act 2008
Patient Protection and Affordable Care/Health Care Education and Reconciliation 2010
Comparative Effectiveness Research
Shift of the system to paying for outcomes
Re-focus towards prevention

Road Blocks and Answers
Physician Uptake
Public Controversy
Education
Challenges for Clinical Trials
Benefits for Clinical Trials
Reimbursement
Co-development

The Personalized Medicine Outlook
Technology Developments
Testing Price
Shifting Strategy
Where do We Go From Here

Appendix